Investor Relations

News Releases

Webcast
Apadaz Update Call
Friday, February 23, 2018 at 2:30 PM EST
Date Title
04/05/16
Summary ToggleKemPharm to Present at the Needham & Company’s 15th Annual Healthcare Conference in New York, NY CORALVILLE, Iowa , April 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
03/28/16
Summary ToggleKemPharm Receives Clearance from FDA to Initiate Human Clinical Trials of KP511, an Investigational Prodrug of Hydromorphone KemPharm plans to develop KP511 as an abuse-deterrent, extended-release product CORALVILLE, Iowa , March 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that its Investigational New Drug (IND) application for KP511, KemPharm’s prodrug of hydromorphone, has been accepted by
03/24/16
Summary ToggleKemPharm Receives NDA User Fee Waiver from FDA CORALVILLE, Iowa , March 24, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration ( FDA ) has granted a fee waiver and has
03/14/16
Summary ToggleKemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP CORALVILLE, Iowa , March 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
03/10/16
Summary ToggleKemPharm, Inc. Reports Q4 and Year End 2015 Results Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights : Submitted New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the U.S.
03/07/16
Summary ToggleKemPharm Files IND for KP511, an Investigational Prodrug of Hydromorphone CORALVILLE, Iowa , March 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) requesting clearance to begin human clinical trials of KP511, KemPharm’s prodrug of
03/02/16
Summary ToggleKemPharm, Inc. to Report Fourth Quarter and Year End 2015 Results Conference Call and Live Audio Webcast Scheduled for March 10, 2016, 4:30 p.m. ET CORALVILLE, Iowa , March 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today
02/19/16
Summary ToggleKemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting CORALVILLE, Iowa , Feb. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced that it will present data from an oral human abuse liability, pharmacokinetic and safety study (KP201.A01) of KP201/APAP, today at the 32 nd Annual Meeting of the American Academy of Pain Medicine (AAPM) in
02/18/16
Summary ToggleKemPharm, Inc. to Present at Upcoming Investor Conferences CORALVILLE, Iowa , Feb. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
02/10/16
Summary ToggleFDA Grants Priority Review to KemPharm for KP201/APAP NDA If Approved, KP201/APAP Could Become the First Immediate-Release Hydrocodone Combination Product With Abuse-Deterrent Properties CORALVILLE, Iowa , Feb. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that the New Drug Application (NDA) for KP201/APAP, its investigational
02/09/16
Summary ToggleKemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021 CORALVILLE, Iowa , Feb. 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the closing of $86.25 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under
02/04/16
Summary ToggleKemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021 CORALVILLE, Iowa , Feb. 04, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH)  announced today the pricing of $75.0 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under
01/07/16
Summary ToggleKemPharm Added to NASDAQ Biotechnology Index CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index
12/30/15
Summary ToggleKemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP746 Novel Prodrug of Oxymorphone Adds New Asset to KemPharm’s Advancing Abuse-Deterrent Product Portfolio CORALVILLE, Iowa , Dec. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary
12/15/15
Summary ToggleKemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA If Approved, KP201/APAP May be the First Immediate Release Hydrocodone Combination Product Candidate for the Treatment of Acute Pain Designed to Address Opioid Abuse and Misuse CORALVILLE, Iowa , Dec. 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), today announced that it has submitted a
12/03/15
Summary ToggleKemPharm, Inc. to Present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY CORALVILLE, Iowa , Dec. 3, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
11/12/15
Summary ToggleKemPharm, Inc. Reports Q3 2015 Results Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Completed Human Abuse Liability Program for KP201/APAP , KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from
11/05/15
Summary ToggleKemPharm, Inc. to Report Third Quarter 2015 Results Conference Call and Live Audio Webcast Scheduled for November 12, 2015, 4:30 p.m. ET CORALVILLE, Iowa , Nov. 5, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today
10/21/15
Summary ToggleKemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP Positive Results From Second Intranasal Human Abuse Liability Clinical Trial Reaffirm Properties of KP201/APAP Conference Call and Live Audio Webcast Scheduled for Today at 5:00 p.m. ET CORALVILLE, Iowa , Oct. 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc.
10/13/15
Summary ToggleKemPharm Enhances U.S. and Global Intellectual Property Estate KemPharm Receives Patent From the USPTO for Novel Prodrug of Methylphenidate, KP415, Additional USPTO Patent Protection for KP201, and Multiple Ex-US Patents for KP511 and KP303 CORALVILLE, Iowa , Oct. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty